

<p><b>7.30–8.30</b>    <b>Registration and breakfast</b></p> <p><b>8.30–8.40</b>    <b>Welcome and introduction</b>  <b>Barbara A. Paldus, Ph.D.</b>,  Vice President and General Manager,  <b>Finesse, part of Thermo Fisher Scientific</b></p> <p><b>8.40–9.15</b>    <b>Life sciences market overview</b>  Investors perspective on the current state and future of the pharma and biotech sectors  <b>Elizabeth Mily</b>, Managing Director,  <b>Barclays Investment Bank</b></p> <p><b>9.15–9.50</b>    <b>Evolutionary and revolutionary process intensification</b>  Revolutionary perfusion in the production bioreactor and an integrated downstream  <b>Jon Coffman</b>, Director of Bioprocess Engineering, <b>Boehringer-Ingelheim</b></p> <p><b>9.50–10.15</b>    <b>Coffee break / refreshments</b></p> <p><b>10.15–10.50</b>    <b>Process intensification enabling technologies</b>  Business and market pressures driving the industry towards more efficient and effective manufacturing models  <b>Jonathan Souquet Ph.D.</b>, Head of Biotech Process Science Technology &amp; Innovation, <b>Merck</b></p> <p><b>10.50–11.25</b>    <b>Customized single-use bioreactors for a new vaccine production plant</b>  High-level overview of vaccine production process and new production plant  <b>Maike Poppema</b>, Product Development Engineer, <b>Janssen Biologics</b></p>	<p><b>11.25–12.00</b>    <b>Overcoming challenges for engineered autologous T cell therapy</b>  CAR-T therapies have created considerable excitement in the medical / scientific community due to spectacular early clinical success in difficult-to-treat haematological cancers  <b>Marc Better</b>, EVP R&amp;D, <b>Kite Pharma</b></p> <p><b>12.00–13.00</b>    <b>Lunch</b></p> <p><b>13.00–13.35</b>    <b>Engineering human T cell circuitry</b>  CRISPR / Cas9 has facilitated genome engineering in many cell types  <b>Alexander Marson</b>, Assistant Professor, Microbiology and Immunology,  <b>UCSF School of Medicine</b></p> <p><b>13.35–14.10</b>    <b>Out of the box strategies and innovative solutions to bring cell therapies to market</b>  Cell therapy industry overview and 2017 update  <b>Ohad Karnieli (PhD, MBA)</b>, CEO, <b>Atvio Biotech</b></p> <p><b>14.10–14.45</b>    <b>Future vision of building a biologics (DS/DP) manufacturing facility in 6 months</b>  Business requirements driving this need and how technology is enabling this reality  <b>Carrier Li</b>, Director for Global Asset Planning, <b>Amgen</b></p> <p><b>14.45–15.20</b>    <b>Process automation for autologous manufacturing – a mid-term view on commercial sustainability</b>  Autologous manufacturing scope, commercial implications, unit operations &amp; cocoon technology  <b>Nina Bauer</b>, Commercial Development, Autologous Manufacturing, <b>Lonza</b></p>	<p><b>15.20–15.45</b>    <b>Coffee break / refreshments</b></p> <p><b>15.45–16.30</b>    <b>Panel discussion: The road to personalized medicine</b>  Personalized or ‘precision’ medicine is on the rise due to advancements in and the emerging integration of biology, biotechnology, DNA sequencing, IT, and IoT  <b>Mark Stevenson</b>,  President of Life Sciences Group,  <b>Thermo Fisher Scientific</b>  <b>Alexander Marson</b>,  Assistant Professor, Microbiology and Immunology,  <b>UCSF School of Medicine</b>  <b>Marc Better</b>,  Executive Vice President R&amp;D, <b>Kite Pharma</b></p> <p><b>16.30</b>    <b>Closing remarks</b></p> <p><b>18.30</b>    <b>Cocktail reception</b></p> <p><b>19.30</b>    <b>Dinner</b></p> <p><b>20.00</b>    <b>Colloidal nonlinear optics for pico-liter protein characterization</b>  Nonlinear optics using optical forces for protein characterization  <b>Nabil M. Lawandy</b>, Chairman, President &amp; CEO,  <b>Spectra Systems Corporation</b></p>
--	--	---

<b>7.30–8.30</b>	<b>Breakfast</b>	<b>11.00–11.15</b>	<b>Coffee break / refreshments</b>	<b>14.35–15.10</b>	<b>“Disposables are not something to throw away. Why single-use is here to stay!”</b>
<b>8.30–8.40</b>	<b>Welcome, day one summary and day two introduction</b>	<b>11.15–11.50</b>	<b>Biosimilars: Trends, benefits and challenges</b>		How bioprocessing steps have been transformed by single-use over the last two decades
	<b>Barbara A. Paldus, Ph.D.,</b> Vice President and General Manager, <b>Finesse, part of Thermo Fisher Scientific</b>		Current global trends and market position		<b>David Valentine</b> , Principal Scientist, Manufacturing Science and Technology, <b>Lonza Biologics</b>
<b>8.40–9.15</b>	<b>The presidential and congressional elections impact on FDA</b>	<b>11.50–12.25</b>	<b>Disposable technology in manufacturing of biosimilar monoclonal antibodies</b>	<b>15.10–15.25</b>	<b>Coffee break / refreshments</b>
	<b>John Taylor</b> , President and Principal, Compliance and Regulatory Affairs, <b>Greenleaf Health Inc.</b>		Project start decision, drivers and how to manage	<b>15.25–16.10</b>	<b>Panel discussion: Smart Technologies – the next-generation smart biomanufacturing facility</b>
<b>9.15–9.50</b>	<b>Opportunities and limits of continuous processing</b>		<b>Adriana Kiełdzińska-Mencfeld</b> , Production Director, <b>Polpharma Biologics</b>		How new and emerging smart technologies for bioprocessing will impact the industry
	The drivers for continuous processing, plus major risks and gaps	<b>12.25–13.00</b>	<b>Case study: Tech transfer of mammalian cell culture process from lab scale to production scale using disposable technology</b>		<b>David Valentine</b> , Principal Scientist, Manufacturing Science and Technology, <b>Lonza Biologics</b>
	<b>Dr. Berthold Boedeker</b> , Chief Scientist, <b>Bayer Pharma AG</b>		Process development, tech transfer, process scale up, final scale and expansion		<b>Jon Coffman</b> , Director of Bioprocess Engineering, <b>Boehringer-Ingelheim</b>
<b>9.50–10.25</b>	<b>Single-use bioreactor scale up: Introduction of a 2000L SUB in 12 months</b>	<b>13.00–14.00</b>	<b>Lunch</b>		<b>Dr. Berthold Boedeker</b> , Chief Scientist, <b>Bayer Pharma AG</b>
	<b>Claire Walsh</b> , Manufacturing Process Specialist, <b>Janssen Sciences</b>	<b>14.00–14.35</b>	<b>Data integrity on the shop floor</b>		<b>Carrier Li</b> , Director for Global Asset Planning, <b>Amgen</b>
<b>10.25–11.00</b>	<b>SmartFactory in action: A year later, Alvotech’s state-of-the-art manufacturing and lab facility</b>		How proper production control and MES enables data integrity	<b>16.10–16.20</b>	<b>Closing remarks</b>
	Introducing a SmartFactory platform, which features an open architecture enabling flexibility to develop and manufacture an impressive line-up of biosimilar products		<b>Robert Perks</b> , Vice President Operations, <b>Werum</b>		
	<b>Fjalar Kristjánsson</b> , Chief Operating Officer, <b>Alvotech</b>				